Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis.

Eur J Heart Fail · 2025 · PMC11798635 · PMID 39252524

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

LVDd also presented a trend toward reduction in the ARNI group; however, the difference did not reach statistical significance (MC: −3.14 mm; 95% CI −7.12, 0.84 when compared to baseline, and MD: −3.98 mm; 95% CI −9.51, 1.54 when compared to the control group) (online supplementary Figure S1A,B ).

also in 111,027 other papers

borderline significantno p-value reported

The findings of this study revealed that ARNI (sacubitril/valsartan) had a borderline significant benefit on all‐cause mortality in HF patients with ESKD undergoing maintenance dialysis (RR 0.64, 95% CI 0.45–0.92).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.